States with restrictive Medicaid policies need to alter those policies because of delayed medical care, according to a recent New England Journal of Medicine letter to the editor.
States with restrictive Medicaid policies need to alter those policies because of delayed medical care, according to a recent New England Journal of Medicine letter to the editor.
Cheryl R. Clark, MD, director of Health Equity Research and Intervention in the Center for Community Health and Health Equity at Brigham and Women’s Hospital and Mark J. Ommerborn, MPH, with Brigham and Women’s Hospital, coauthored new Medicaid research that was published in the NEJM letter, published March 28, 2013.
Dr Clark and colleagues examined county-level geographic variation in the prevalence of delayed care–specifically seeing a physician–because of cost among 280,333 adults in the 2010 Behavioral Risk Factor Surveillance System (BRFSS) survey. The researchers also reviewed the relationship between Medicaid eligibility thresholds for working adults with children and the odds that BRFSS survey participants would delay seeking care.
“Our results suggest stark geographic differences in the prevalence of care delayed because of cost. States and counties with a high prevalence of delayed care had a weaker health care infrastructure than states with a lower prevalence of delayed care,” Dr Clark wrote. Particularly vulnerable areas were in the South, including Texas and Florida.
Populations in counties with the highest prevalence of delayed care were more likely to be Hispanic and have low incomes and a high prevalence of chronic disease. “And, these areas had a relatively low history of state Medicaid expansion,” Dr Clark wrote.
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More